外周动脉疾病抗血栓治疗结构化综述:聚焦血运重建的TASC倡议
外周动脉疾病影响全球超2亿人,血运重建可改善症状但术后心血管与肢体事件风险升高,与动脉血栓形成和再狭窄相关。支持术后抗血小板和抗凝治疗的高质量随机数据有限,部分依据 extrapolated 自经皮冠状动脉介入文献,指南推荐不一致且不总是基于证据。本结构化综述评估外周动脉血运重建后抗血栓治疗的现有随机数据,聚焦影响结果解读的临床试验设计问题,并指出需进一步研究的领域。
要点
- 外周动脉疾病影响全球超200亿人,与显著肢体和心血管疾病负担相关。
- 血运重建后心血管和肢体事件基线风险升高,与动脉血栓形成和再狭窄相关。
- 支持血运重建后抗血栓治疗的高质量随机数据有限,指南推荐不一致且不总是基于证据。
核心结论
- 支持外周动脉疾病血运重建后抗血栓治疗的高质量随机数据有限,指南推荐不一致且不总是基于证据。
研究设计与样本
- TASC倡议的结构化综述,评估外周动脉血运重建后抗血栓治疗的现有随机数据。
主要发现
- 外周动脉疾病影响全球超2亿人,与显著肢体和心血管疾病负担相关。
- 稳定外周动脉疾病患者血运重建后心血管和肢体事件基线风险升高,与动脉血栓形成和再狭窄相关。
- 支持血运重建后抗血小板和抗凝治疗的高质量随机数据有限,部分依据 extrapolated 自经皮冠状动脉介入文献。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Peripheral artery disease affects >200 million people worldwide and is associated with significant limb and cardiovascular morbidity and mortality. Limb revascularization is recommended to improve function and quality of life for symptomatic patients with peripheral artery disease with intermittent claudication who have not responded to medical treatment. For patients with critical limb ischemia, the goals of revascularization are to relieve pain, help wound healing, and prevent limb loss. The baseline risk of cardiovascular and limb-related events demonstrated among patients with stable peripheral artery disease is elevated after revascularization and related to atherothrombosis and restenosis. Both of these processes involve platelet activation and the coagulation cascade, forming the basis for the use of antiplatelet and anticoagulant therapies to optimize procedural success and reduce postprocedural cardiovascular risk. Unfortunately, few high-quality, randomized data to support use of these therapies after peripheral artery disease revascularization exist, and much of the rationale for the use of antiplatelet agents after endovascular peripheral revascularization is extrapolated from percutaneous coronary intervention literature. Consequently, guideline recommendations for antithrombotic therapy after lower limb revascularization are inconsistent and not always evidence-based. In this context, the purpose of this structured review is to assess the available randomized data for antithrombotic therapy after peripheral arterial revascularization, with a focus on clinical trial design issues that may affect interpretation of study results, and highlight areas that require further investigation.
引用
- Hess CN, Norgren L, Ansel GM, et al. A Structured Review of Antithrombotic Therapy in Peripheral Artery Disease With a Focus on Revascularization: A TASC (InterSociety Consensus for the Management of Peripheral Artery Disease) Initiative. Circulation. 2017. PMID: 28630267. doi:10.1161/CIRCULATIONAHA.117.024469
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。